Low-mutation-rate, reducedgenome *Escherichia coli*: an improved host for faithful maintenance of engineered genetic constructs

Csörgő B, Fehér T, Tímár, Blattner FR, Pósfai G. *Microbial Cell Factories* (2012), 11:11.

Presented by Queenie Chan April 18, 2012

Background

Genetic variation

- In <u>nature</u>: leads to evolution & survival of the fittest
- In <u>lab conditions</u>: not favorable, can lead to unwanted genotypic and phenotypic alterations


How do mutations arise?

- Stress → SOS response
 - DNA polymerases: can bypass damaged sites and stalled replication forks; create mutations

Pol II

Pol IV

Pol V



Goal

- Create chassis that allows stable production of growth-inhibiting biomolecules for applications in synthetic and molecular bio
- Why growth-inhibiting biomolecules, specifically?
 - Mutants usually positively selected for

Project

- MG1655: wild-type E. coli strain
- MDS42: reduced genome *E. coli* strain
 - Genes irrelevant for lab applications (such as insertion sequences) deleted
 - Modifying MDS42 by creating variants that are more genetically stable
 - II. Evaluated variants under stressful conditions
 - III. Evaluated variants transformed with toxicproduct-producing gene


Creating Variants

Measuring mutation rates of variants


Polymerase : gene

Pol II : polB Pol IV : dinB


Pol V: umuDC




Evaluating under Stressful Conditions




Evaluating with Toxic Protein Gene





Test with Toxic Protein Gene

Measuring number of mutants in different strains over time



Conclusion

- Eliminating 3 polymerases involved in SOS response significantly decreases mutation rates
- MDS42pdu most genetically stable variation of MDS42
 - Lowest rate of mutation in response to:
 - Stressful conditions
 - Production of toxic products

Significance

- Developed chassis that is able to stably produce growth-inhibiting biomolecules
- Applications:
 - Synthetic & molecular biology
 - Biotechnology
 - Cloning
 - DNA therapeutics


Concerns

- Explanation for MDS42pd's (double gene deletion) slightly lower mutation rate than MDS42pdu (triple gene deletion)
- Explanation for difference in MDS42lexA (S119A) and MDS42recA (regulator mutants)'s reaction to stress
- Inclusion of BL21(DE3)


Questions?

Supplementary Slides: Creating Variants

Verifying that variations do not affect normal cell growth



Supplementary Slides: Characterizing Types of Mutations



Supplementary Slides: Checking IPTG Inducibility of strains

